Designing Life from Scratch: A Fledgling Field is About to Take Off
By Lisa M. Krieger,
San Jose Mercury News
| 08. 08. 2015
Untitled Document
Mother Nature has always been life's master architect, working off genetic blueprints that are fine-tuned from one generation to the next.
Until now.
Scientists increasingly are designing life from scratch, using inexpensive, fast and accurate tools to create and assemble strands of DNA like tinkertoys -- and instructing cells to do things that nature never imagined.
In industrial clusters in the Bay Area, La Jolla and Boston, the competitive gene-building field is doing for biology what Johannes Gutenberg did for printing -- turning what was once a laborious and uneven artisan effort into affordable and accurate mass production. With the potential to create an industry that could lead to products worth hundreds of billions of dollars, the fast-moving field is not only prompting investor funding but also sparking calls for oversight.
The goal is to build improved medicines, better biofuels and new chemicals -- and perhaps someday splice new genes into sick people, fixing inherited diseases. But the cutting-edge technique also could be used to build dangerous pathogens for warfare.
"We're accelerating genetics," said biochemist Emily Leproust, cofounder...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...